S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 168 HKD -4.27% Market Closed
Market Cap: 36.3B HKD
Have any thoughts about
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?
Write Note

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Accounts Payable
ÂĄ404.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Payable
ÂĄ1.1B
CAGR 3-Years
25%
CAGR 5-Years
85%
CAGR 10-Years
39%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
41%
CAGR 5-Years
47%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View

Market Cap
37.4B HKD
Industry
Biotechnology

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Chengdu, Sichuan and currently employs 1,155 full-time employees. The company went IPO on 2023-07-11. Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The firm is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Intrinsic Value
144.55 HKD
Overvaluation 14%
Intrinsic Value
Price
S

See Also

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Accounts Payable?
Accounts Payable
404.4m CNY

Based on the financial report for Dec 31, 2023, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Accounts Payable amounts to 404.4m CNY.

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 1Y
13%

Over the last year, the Accounts Payable growth was 13%.

Back to Top